Purpose :To evaluate the relationship between the serum levels of IL-1α, IL-1β, sIL-1ra and the activity and the severity of Graves’ Ophthalmopathy(GO), as well as the therapeutic responses to high-dose IV methylprednisolone.Methods: Using enzyme linked immunosorbent assay (ELISA) systems, we measured serum concentrations of IL-1αIL-1β and sIL-1ra in 18 normal controls, 20 active GO, 20 inactive GO, 18 Graves’ disease(GD) on patients without ophthalmopathy and 10 active GO patients after high-dose Ⅳ methylprednisolone therapy.Results : The baseline median sIL-1ra concentrations had no significant differences among active GO, inactive GO, GD and control groups. There was no correlation between baseline sIL-1ra levels and the severity of GO, cigarette smoking, and the responses to glucocorticoids therapy. However, responders had higher sIL-1ra levels (626. 97± 305.06 pg/ml) after glucocorticoids therapy than nonresponders (323. 33 ± 93. 09 pg/ml). The concentration of IL-1α,IL-1β (< 3. 9 pg/ml)in Purpose: To evaluate the relationship between the serum levels of IL-1α, IL-1β, sIL-1ra and the activity and the severity of Graves’ Ophthalmopathy (GO), as well as the therapeutic responses to high-dose IV methylprednisolone. Methods : Using enzyme linked immunosorbent assay (ELISA) systems, we measured serum concentrations of IL-1α IL-1β and sIL-1ra in 18 normal controls, 20 active GO, 20 inactive GO, 18 Graves’ disease (GD) on patients without ophthalmopathy and 10 active GO patients after high-dose IV methylprednisolone therapy. Results: The baseline median sIL-1ra concentrations had no significant differences among active GO, inactive GO, GD and control groups. There was no correlation between baseline sIL-1ra levels and the severity However, responders had higher sIL-1ra levels (626. 97 ± 305.06 pg / ml) after glucocorticoids therapy than nonresponders (32.33 ± 93. 09 pg / ml). The concentration of IL-1α, IL-1 β (<3.9 pg / ml) in